Invasive Fungal Infections Market Industry Analysis Covering Trends, Drivers, And Future Outlook
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Larger Will The Invasive Fungal Infections Market Become By 2030 Compared To 2026?
The market for invasive fungal infections has shown consistent growth over recent years. It is projected to expand from $7.91 billion in 2025 to $8.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. Historically, this market’s expansion can be attributed to several factors, including the increasing prevalence of HIV and cancer patients, the widespread use of broad-spectrum antibiotics, the established application of amphotericin b in hospitals, a rise in organ transplant procedures, and the growing incidence of hospital-acquired fungal infections.
The market for invasive fungal infections is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $10.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This projected growth is primarily driven by factors such as the emergence of new antifungal drug categories, heightened recognition of antifungal resistance, an expanding critical care infrastructure, enhanced diagnostic tools for fungal infections, and increased funding for infectious disease research. Key trends anticipated during this period encompass a higher occurrence of invasive fungal infections in immunocompromised individuals, wider acceptance of echinocandins as initial treatment, more frequent utilization of combined antifungal therapies, the broadening of hospital-based antifungal stewardship initiatives, and an increasing need for both broad-spectrum and specific antifungal agents.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp
What Market Drivers Are Helping Shape The Invasive Fungal Infections Market Expansion?
The growing number of individuals with human immunodeficiency virus (HIV) is projected to boost the invasive fungal infection market. HIV, a virus, weakens the immune system, making it harder to fight off diseases. This increased vulnerability in people with conditions like HIV or AIDS (acquired immunodeficiency syndrome) heightens their risk of invasive fungal infections, thereby encouraging manufacturers to create more specialized and effective antifungal treatments. For example, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based international organization, reported in July 2025 that 40.8 million [37.0 million–45.6 million] people were living with HIV in 2024. During that same year, approximately 1.3 million [1 million–1.7 million] new HIV infections occurred, and 630 000 [490 000–820 000] individuals died from AIDS-related illnesses. Consequently, the expanding population affected by human immunodeficiency virus (HIV) will stimulate the growth of the invasive fungal infection market.
What Are The Core Segment Classifications In The Invasive Fungal Infections Market?
The invasive fungal infections market covered in this report is segmented –
1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Types
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Types
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis
2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation
3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis
4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis
5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis
6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections
Which Trends Are Contributing To Changes In The Invasive Fungal Infections Market?
Key companies within the invasive fungal infection market are concentrating on innovative offerings like Zisavel capsules to enhance treatment effectiveness, improve patient outcomes, and broaden accessibility for those impacted by serious fungal infections. Zisavel capsules are a generic antifungal medication derived from isavuconazole, specifically formulated to address invasive aspergillosis and mucormycosis. These 100 mg capsules aim to provide a more affordable alternative for patients, thereby improving access to effective treatment. For instance, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, launched Zisavel Capsules, a generic antifungal drug, for managing invasive aspergillosis and mucormycosis. Zisavel is indicated for the treatment of invasive aspergillosis and mucormycosis, both of which are severe fungal infections that can be life-threatening. The introduction of Zisavel seeks to make treatment more accessible to patients by significantly reducing costs compared to current options such as voriconazole and posaconazole.
Which Companies Form The Competitive Landscape Of The Invasive Fungal Infections Market?
Major companies operating in the invasive fungal infections market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB
Access The Complete Invasive Fungal Infections Market Report:
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Which Geographic Region Represents The Largest Invasive Fungal Infections Market Share?
North America was the largest region in the invasive fungal infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Invasive Fungal Infections Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=13189&type=smp
Browse Through More Reports Similar to the Global Invasive Fungal Infections Market 2026, By The Business Research Company
Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2026
Invasive Fungal Infections Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Fungal Protein Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/fungal-protein-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
